search
Back to results

Transcranial Ultrasonography for the Management of Patients With Mild TBI (TRUST)

Primary Purpose

Mild Traumatic Brain Injury

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Transcranial Doppler (TCD)
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Mild Traumatic Brain Injury focused on measuring Transcranial Doppler

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild TBI (GCS 13-15 on ED admission) with one of the following:
  • Patient with minor cerebral lesion on initial CT scan (TCDBII i.e. no midline shift, visible basal cisterns and haemorrhagic lesion < 25 cc) and GCS 15 after CT scan
  • OR * Patient with normal initial CT scan (TCDB I) with at least one risk factor :

    • GCS = 14 after CT scan
    • and/or alcoholic intoxication
    • and/or on-going treatment with aspirin
    • and /or persisting nausea, and/or vomiting and/or headaches
    • Early initial CT scan (< 4 hours after TBI)
  • Possibility of home supervision by a third-party
  • Affiliation to the French social security system
  • Patient have signed consent form
  • Possibility to perform a TCD within 8 hours
  • Stable hemodynamics: systolic blood pressure >90 mmHg, peripheral capillary oxygen saturation >92%, hemoglobin > 8 g/dl

Exclusion Criteria:

  • CT scan classified as TCDB III - VI
  • Penetrating head-trauma
  • Patient under mechanical ventilation
  • Patients treated with anticoagulants or anti-platelet therapy (except Aspirin)
  • Hospitalization required by post-traumatic extra-cranial lesion, intoxication (except alcoholic), pre-existing condition (including congenital hemostasis disorders) or social factors at the discretion of the physician.
  • Internal Carotid dissection
  • Post-traumatic lesion in the posterior cerebral fossa
  • Subject in exclusion period of another interventional study,
  • Pregnant women, breastfeeding women
  • Subject under administrative or judicial control, under protection

Sites / Locations

  • CH Bourg-en-bresse
  • CHU Clermont-FerrandRecruiting
  • CHU Grenoble AlpesRecruiting
  • CHRU LilleRecruiting
  • HCL - Edouard HerriotRecruiting
  • HCL - Lyon Sud
  • AP-HM Timone
  • CH MelunRecruiting
  • CHRU Montpellier
  • CHU NantesRecruiting
  • CHU Nîmes
  • AP-HP - Avicenne
  • AP-HP LariboisièreRecruiting
  • AP-HP Pitié SalpetrièreRecruiting
  • CHU PoitiersRecruiting
  • Chu ReunionRecruiting
  • CHU RéunionRecruiting
  • CHU ToulouseRecruiting
  • CH MonacoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

TCD Group

CONTROL Group

Arm Description

Transcranial Doppler within 8 hours of traumatic injury

Mild TBI management with SFMU recommandations

Outcomes

Primary Outcome Measures

Non-inferiority of a TCD-based strategy after a mild TBI to the standard management in terms of the overall neurological outcome
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.

Secondary Outcome Measures

Effects of a TCD-based strategy after a mild TBI on the overall neurological outcome
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.
Effects of a TCD-based strategy after a mild TBI on the quality of life
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
Effects of a TCD-based strategy after a mild TBI on the quality of life
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
Effects of a TCD-based strategy after a mild TBI on Morbidity after TBI
Number of cerebral CT scans within the hospital stay, • Thromboembolic events or diagnosed nosocomial infections stay
Effects of a TCD-based strategy after a mild TBI on mortality after TBI
Mortality within the first 3 months
Effects of a TCD-based strategy after a mild TBI on patient safety
Number of patients with neurologic worsening within the first week after TBI.

Full Information

First Posted
June 14, 2019
Last Updated
November 7, 2022
Sponsor
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT03989999
Brief Title
Transcranial Ultrasonography for the Management of Patients With Mild TBI
Acronym
TRUST
Official Title
Transcranial Ultrasonography for the Management of Patients With Mild Traumatic Brain Injury
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2020 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
July 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesize that patients with mild TBI and normal TCD can be safely discharged home immediately after the ED. The targeted population is the category of patients eligible for early discharge: 1) patients with mild lesions on the initial CT scan and a GCS 15 after CT scan completion and, 2) patients with no lesion on the initial cerebral CT scan with at least one of the following risk factors: GCS 14 after CT scan completion, persisting post-traumatic nausea/vomiting/headaches, concomitant alcoholic intoxication or patients treated with aspirin. The study will not include mild TBI patients who are not eligible for early discharge: patients with no possibility of home supervision, those with a GCS lower than 14 after the CT scan or those treated with anticoagulant/antiplatelet drugs other than aspirin. The investigators expect the TCD-based strategy to be non-inferior compared to the standard strategy according to French recommendations in terms of the 3-months neurological outcome. From a public health standpoint, the use of TCD as a triage tool may change current guidelines regarding mild TBI management.
Detailed Description
Patients with mild traumatic brain injury (TBI) represent the vast majority of TBI patients admitted in the emergency department (ED). According to French recommendations, mild TBI patients with brain lesions on initial CT scan are directed to a standard ward, where neurologic monitoring consists of repeated CT scanning and clinical exams. Patients with no lesion on initial cerebral CT scan are also hospitalized 1) when their GCS after CT scan is lower than 15, 2) in case of persisting nausea, vomiting or headache, 3) in case of concomitant alcoholic intoxication and, 4) in case of on-going treatment with aspirin. This strategy induces significant hospital stay with potential morbidity, whereas neurologic worsening rarely occurs. In this context, the implementation of a triage tool in the ED would be useful to screen patients at risk of early neurologic worsening. Hence, low risk patients may be discharged at home immediately after the ED. Transcranial Doppler (TCD) is a non-invasive technique that measures cerebral blood flow velocities in intracranial cerebral arteries. These velocities and a derivated parameter (pulsatility index, PI), estimate cerebral blood flow (CBF) and have become a standard of care to optimize CBF in after severe TBI. Only few studies report the use of TCD after mild TBI. In a single-center cohort of patients with mild-to-moderate TBI, TCD parameters measured at hospital admission accurately predicted early neurologic worsening. These encouraging results indicate that TCD, in combination with CT scan findings, could play a role in the management of patients with mild TBI. The aim of this project is to determine whether a TCD-based strategy is non-inferior to the standard management in terms of the overall neurological outcome at 3 months after mild TBI with no/minor lesions detected on a cerebral CT scan.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Traumatic Brain Injury
Keywords
Transcranial Doppler

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, multicenter, open, non-inferiority, randomized, controlled, study with blinded evaluation.
Masking
Outcomes Assessor
Masking Description
The evaluation at 3 months after TBI will be centralized by the coordinating centre and blinded.
Allocation
Randomized
Enrollment
984 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TCD Group
Arm Type
Experimental
Arm Description
Transcranial Doppler within 8 hours of traumatic injury
Arm Title
CONTROL Group
Arm Type
No Intervention
Arm Description
Mild TBI management with SFMU recommandations
Intervention Type
Procedure
Intervention Name(s)
Transcranial Doppler (TCD)
Intervention Description
In the Emergency Department (ED): After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury. If TCD is normal (FVd>25 cm/sec and PI <1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (< 4-6 hours after TBI), CT scan should not be controlled before patient discharge. If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward). No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group.
Primary Outcome Measure Information:
Title
Non-inferiority of a TCD-based strategy after a mild TBI to the standard management in terms of the overall neurological outcome
Description
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.
Time Frame
3 months after TBI
Secondary Outcome Measure Information:
Title
Effects of a TCD-based strategy after a mild TBI on the overall neurological outcome
Description
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.
Time Frame
1 month after TBI
Title
Effects of a TCD-based strategy after a mild TBI on the quality of life
Description
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
Time Frame
1 months after TBI
Title
Effects of a TCD-based strategy after a mild TBI on the quality of life
Description
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
Time Frame
3 months after TBI
Title
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Description
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
Time Frame
1 month after TBI
Title
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Description
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
Time Frame
3 months after TBI
Title
Effects of a TCD-based strategy after a mild TBI on Morbidity after TBI
Description
Number of cerebral CT scans within the hospital stay, • Thromboembolic events or diagnosed nosocomial infections stay
Time Frame
1 months after TBI
Title
Effects of a TCD-based strategy after a mild TBI on mortality after TBI
Description
Mortality within the first 3 months
Time Frame
3 months after TBI
Title
Effects of a TCD-based strategy after a mild TBI on patient safety
Description
Number of patients with neurologic worsening within the first week after TBI.
Time Frame
3 months after TBI

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mild TBI (GCS 13-15 on ED admission) with one of the following: Patient with minor cerebral lesion on initial CT scan (TCDBII i.e. no midline shift, visible basal cisterns and haemorrhagic lesion < 25 cc) and GCS 15 after CT scan OR * Patient with normal initial CT scan (TCDB I) with at least one risk factor : GCS = 14 after CT scan and/or alcoholic intoxication and/or on-going treatment with aspirin and /or persisting nausea, and/or vomiting and/or headaches Early initial CT scan (< 4 hours after TBI) Possibility of home supervision by a third-party Affiliation to the French social security system Patient have signed consent form Possibility to perform a TCD within 8 hours Stable hemodynamics: systolic blood pressure >90 mmHg, peripheral capillary oxygen saturation >92%, hemoglobin > 8 g/dl Exclusion Criteria: CT scan classified as TCDB III - VI Penetrating head-trauma Patient under mechanical ventilation Patients treated with anticoagulants or anti-platelet therapy (except Aspirin) Hospitalization required by post-traumatic extra-cranial lesion, intoxication (except alcoholic), pre-existing condition (including congenital hemostasis disorders) or social factors at the discretion of the physician. Internal Carotid dissection Post-traumatic lesion in the posterior cerebral fossa Subject in exclusion period of another interventional study, Pregnant women, breastfeeding women Subject under administrative or judicial control, under protection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pierre BOUZAT, MD, PhD
Phone
+33 (0)4 76 76 67 29
Email
pbouzat@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anaïs ADOLLE
Phone
+33 (0)4 76 76 67 29
Email
arcpar@chu-grenoble.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre BOUZAT, MD, PhD
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
CH Bourg-en-bresse
City
Bourg-en-Bresse
Country
France
Individual Site Status
Withdrawn
Facility Name
CHU Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe PERRIER, MD
Facility Name
CHU Grenoble Alpes
City
Grenoble
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maxime MAIGNAN, MD
First Name & Middle Initial & Last Name & Degree
DAMIEN VIGLINO, MD
Facility Name
CHRU Lille
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Delphine GARRIGUE, MD
Facility Name
HCL - Edouard Herriot
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karim TAZAROURTE, MD, PhD
Facility Name
HCL - Lyon Sud
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marion DOUPLAT, MD
Facility Name
AP-HM Timone
City
Marseille
Country
France
Individual Site Status
Withdrawn
Facility Name
CH Melun
City
Melun
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David SAPIR, MD
Facility Name
CHRU Montpellier
City
Montpellier
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mustapha SEBBANE, MD, PhD
Facility Name
CHU Nantes
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe PES, MD
Facility Name
CHU Nîmes
City
Nîmes
Country
France
Individual Site Status
Withdrawn
Facility Name
AP-HP - Avicenne
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurélien GUENIN, MD
Facility Name
AP-HP Lariboisière
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony CHAUVIN, MD
Facility Name
AP-HP Pitié Salpetrière
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martha Cancella de Abreu, MD, PhD
Facility Name
CHU Poitiers
City
Poitiers
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeremy GUENEZAN, MD
Facility Name
Chu Reunion
City
Saint Pierre
ZIP/Postal Code
97448
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nathalia EBRAN, MD
First Name & Middle Initial & Last Name & Degree
ADRIEN VAGUE, MD
Facility Name
CHU Réunion
City
Saint-Denis
ZIP/Postal Code
97400
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bertrand GUIHARD, MD
Facility Name
CHU Toulouse
City
Toulouse
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles Henri Houzé-Cerfon, MD
Facility Name
CH Monaco
City
Monaco
Country
Monaco
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yann-Erick CLAESSENS, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29122524
Citation
Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P, Brazinova A, Buki A, Chesnut RM, Citerio G, Coburn M, Cooper DJ, Crowder AT, Czeiter E, Czosnyka M, Diaz-Arrastia R, Dreier JP, Duhaime AC, Ercole A, van Essen TA, Feigin VL, Gao G, Giacino J, Gonzalez-Lara LE, Gruen RL, Gupta D, Hartings JA, Hill S, Jiang JY, Ketharanathan N, Kompanje EJO, Lanyon L, Laureys S, Lecky F, Levin H, Lingsma HF, Maegele M, Majdan M, Manley G, Marsteller J, Mascia L, McFadyen C, Mondello S, Newcombe V, Palotie A, Parizel PM, Peul W, Piercy J, Polinder S, Puybasset L, Rasmussen TE, Rossaint R, Smielewski P, Soderberg J, Stanworth SJ, Stein MB, von Steinbuchel N, Stewart W, Steyerberg EW, Stocchetti N, Synnot A, Te Ao B, Tenovuo O, Theadom A, Tibboel D, Videtta W, Wang KKW, Williams WH, Wilson L, Yaffe K; InTBIR Participants and Investigators. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017 Dec;16(12):987-1048. doi: 10.1016/S1474-4422(17)30371-X. Epub 2017 Nov 6. No abstract available.
Results Reference
background
PubMed Identifier
16311842
Citation
Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien). 2006 Mar;148(3):255-68; discussion 268. doi: 10.1007/s00701-005-0651-y.
Results Reference
background
PubMed Identifier
17297312
Citation
Davis DP, Kene M, Vilke GM, Sise MJ, Kennedy F, Eastman AB, Velky T, Hoyt DB. Head-injured patients who "talk and die": the San Diego perspective. J Trauma. 2007 Feb;62(2):277-81. doi: 10.1097/TA.0b013e31802ef4a3.
Results Reference
background
PubMed Identifier
15662058
Citation
af Geijerstam JL, Britton M. Mild head injury: reliability of early computed tomographic findings in triage for admission. Emerg Med J. 2005 Feb;22(2):103-7. doi: 10.1136/emj.2004.015396.
Results Reference
background

Learn more about this trial

Transcranial Ultrasonography for the Management of Patients With Mild TBI

We'll reach out to this number within 24 hrs